1. Market Research
  2. > Healthcare Market Trends
  3. > U.S. Markets for Obesity Drugs & Devices

U.S. Markets for Obesity Drugs & Devices

  • February 2015
  • -
  • Medtech Insight

According to National Health and Nutrition Examination Survey (NHANES), approximately 35%, or nearly one out of three adults age 20 years or older were classified as obese in 2012 (the latest available statistics) based on a BMI of 30 kg/m2 or greater. This translates to more than 100 million obese people in the U.S.—a staggering number. Obesity has become such as concern due to increasing prevalence and the rise of serious health-related co-morbidities, such as type 2 diabetes, that it has recently been recognized by the American Medical Association, as well as other medical and government organizations, as a chronic disease. Due to the fact that type 2 diabetes and obesity are closely linked, the rise of obesity is increasing the prevalence of diabetes, making it critical to develop improved medical treatments to more effectively treat both conditions.

The fact that the overweight, obese and morbidly obese population remains vastly undertreated (in the U.S. and worldwide) bodes very well for next-generation obesity drugs and devices, as it leaves significant room for companies to profit and grow revenues in the coming decade in a virtually untapped U.S. market, expected to be valued at more than $1.8 billion by the year 2020.

This dynamic, new report from Medtech Insight includes analyses of selected products, current/forecast markets, surgical procedure volumes, competitors, market share by supplier, and opportunities in the U.S. Obesity Drugs and Devices Market. Specifically, this report covers leading and emerging prescription-based weight loss (obesity) drugs, and minimally invasive medical devices, including: laparoscopic adjustable gastric banding (LAGB) systems, intragastric balloon systems, implantable gastric stimulation devices, and other emerging device-based technologies, including nonsurgical/incisionless, transorally inserted or next-generation minimally invasive weight loss device therapies.

In 2014, the total, combined U.S. market for “new” obesity drugs and (minimally invasive medical) devices for the treatment of obesity was estimated at approximately $374.7 million. Over the forecast period, the total market is expected to advance at a healthy, double-digit compound annual rate of 32.4%, from an estimated $455.4 million in 2015 to an estimated $1,852.1 million in the year 2020.

Table Of Contents

U.S. Markets for Obesity Drugs and Devices
TABLE OF CONTENTS

EXECUTIVE SUMMARY
i US Obesity Drugs and Devices Market
Ii Methodology

Exhibit ES-1: US Obesity Drugs and Devices
Market, 2013-2020

1 OBESITY DRUGS
11 Leading Obesity Drugs
111 Genentech/Roche Group (Xenical)
112 Vivus (Qsymia)
113 Arena Pharmaceuticals/Eisai (Belviq)
114 Orexigen Therapeutics/Takeda
(Contrave)
12 Emerging Obesity Drugs
121 Gelesis (Gelesis100)
122 Hanmi Pharmaceuticals
(LAPS CA-Exendin-4/HPP4404)
123 Novo Nordisk (Saxenda)
1231 Victoza (liraglutide)
124 Orexigen Therapeutics (Empatic)
125 Rhythm Pharmaceuticals (RM-493)
126 Zafgen (Beloranib)
13 Market Analysis
131 Market Forecast
1311 Market Drivers
1312 Market Limiters
132 Competitive Analysis

Exhibit 1-1: 2015, FDA Approved Obesity Drugs
Exhibit 1-2: Xenical, SWOT Analysis
Exhibit 1-3: Qsymia, SWOT Analysis
Exhibit 1-4: Belviq, SWOT Analysis
Exhibit 1-5: Contrave, SWOT Analysis
Exhibit 1-6: 2015, Selected Obesity Drugs
Recently FDA Approved or Under
Development
Exhibit 1-7: Gelesis100 Mechanism of Action
Exhibit 1-8: New Obesity Drugs, Market Forecast,
2013-2020
Exhibit 1-9: 2013, New Obesity Drugs Market,
Share by Supplier
Exhibit 1-10: 2014, New Obesity Drugs
Market, Share by Supplier

2 LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING SYSTEMS
21 Leading LAGB Systems
211 Apollo Endosurgery
212 Ethicon Endo-Surgery/
Johnson and Johnson
213 Other LAGB Systems
(Available Outside the US)
2131 Agency for Medical
Innovations
2132 Cousin Biotech
2133 Helioscopie
2134 Medical Innovation
Developpement
22 Market Analysis
221 Procedure Volumes Forecast
222 Market Forecast

2221 Market Drivers
2232 Market Limiters
223 Competitive Analysis

Exhibit 2-1: Risks Associated with Gastric Banding and Abdominal/Bariatric Surgery
Exhibit 2-2: 2015, Laparoscopic Adjustable
Gastric Banding Systems
Exhibit 2-3: Apollo EndoSurgery's LAP-BAND
Exhibit 2-4: Key Benefits and Risks of the
LAP-BAND Procedure
Exhibit 2-5: Excess Weight Loss with the
LAP-BAND System Compared to
Roux-en-Y Gastric Bypass at 3
Years and Beyond
Exhibit 2-6: Ethicon Endo-Surgery's Curved
Adjustable Gastric Endo Band,
Features and Benefits
Exhibit 2-7: Comparison of Gastric Banding,
Gastric Bypass, and Sleeve
Gastrectomy
Exhibit 2-8: Agency for Medical Innovations'
Soft Gastric Band Premium
Exhibit 2-9: Cousin Biotech's Bioring
Adjustable Gastric Band
Exhibit 2-10: Helioscopie's Heliogast HAGA
Adjustable Gastric Band
Exhibit 2-11: Medical Innovation
Developpement's MIDBAND
Adjustable Gastric Band
Exhibit 2-12: Laparoscopic Adjustable Gastric
Banding, Procedure Volumes
Forecast, 2013-2020
Exhibit 2-13: Estimated Number of Bariatric
Surgeries, US Procedure
Volumes Forecast, 2013-2020
Exhibit 2-14: 2015 and 2020, Comparison of
Estimated Bariatric Surgical
Volumes, by Percentage and
Type of Surgery
Exhibit 2-15: Laparoscopic Adjustable Gastric
Banding, Market Forecast,
2013-2020
Exhibit 2-16: 2013, Laparoscopic Adjustable
Gastric Banding Systems,
Share by Supplier
Exhibit 2-17: 2014, Laparoscopic Adjustable
Gastric Banding Systems
Market, Share by Supplier

3 INTRAGASTRIC BALLOON SYSTEMS
31 Apollo Endosurgery
32 Helioscopie
33 ReShape Medical
34 Spatz FGIA
35 Obalon Therapeutics
36 Market Analysis
361 Market Drivers
362 Market Limiters



Exhibit 3-1: Apollo Endosurgery's Orbera
Managed Weight Loss System
Exhibit 3-2: Helioscopie's Heliosphere
Intragastric Balloon
Exhibit 3-3: ReShape Duo Intragastric
Balloon System
Exhibit 3-4: REDUCE Pivotal Trial Results
Exhibit 3-5: The Spatz Adjustable Balloon
System
Exhibit 3-6: Risks of Intragastric Balloon
Placement
Exhibit 3-7: The Spatz Adjustable Balloon
Procedure
Exhibit 3-8: The Obalon Gastric Balloon
System Features and Possible
Complications
Exhibit 3-9: Intragastric Balloon Therapy,
Procedure Volumes Forecast,
2015-2020
Exhibit 3-10: Intragastric Balloon Systems,
Market Forecast, 2015-2020

4 IMPLANTABLE VAGAL BLOCKING THERAPY
41 EnteroMedics
42 MetaCure
43 Market Analysis
431 Market Drivers
432 Market Limiters

Exhibit 4-1: 2015, Implantable Pulse
Generators Developed for the
of Obesity
Exhibit 4-2: EnteroMedics' Maestro System
Exhibit 4-3: Overview of EnteroMedics'
VBLOC Therapy and Vagus
Nerve Function
Exhibit 4-4: Potential Benefits and Risks of
VBLOC Therapy
Exhibit 4-5: Comparison of VBLOC Therapy,
Laparoscopic Banding, and
Gastric Bypass
Exhibit 4-6: MetaCure's DIAMOND
(TANTALUS) Gastric Stimulation
System
Exhibit 4-7: Implantable VBLOC Therapy
Devices, EnteroMedics,
Procedure Volumes Forecast,
2015-2020
Exhibit 4-8: Implantable VBLOC Therapy
Devices, EnteroMedics, Market
Forecast, 2015-2020

5 OTHER EMERGING MEDICAL DEVICE TECHNOLOGIES
51 Aspire Bariatrics
52 BAROnova
53 EndoSphere, Inc
54 GI Dynamics
55 Onciomed
56 Scientific Intake
57 TransEnterix

59 USGI Medical
59 Others

Exhibit 5-1: 2015, Selected Emerging Medical
Device Technologies for the
Treatment of Obesity
Exhibit 5-2: Aspire Bariatric's AspireAssist
Exhibit 5-3: EndoSphere's SatiSphere
Exhibit 5-4: GI Dynamic's EndoBarrier
Gastrointestinal Liner and
Procedure
Exhibit 5-5: Scientific Intake's SMART Device
Exhibit 5-6: USGI Medical's Incisionless
Operating Platform
Exhibit 5-7: Primary Obesity Surgery,
Endolumenal

TOTAL US OBESITY DRUGS AND DEVICES MARKET
i New Obesity Drugs Market
ii Obesity Devices Market

Exhibit 6-1: US Obesity Drugs and Devices
Market, 2013-2020
Exhibit 6-2: US New Obesity Drugs Market,
2013-2020
Exhibit 6-3: US Obesity Devices Market,
2013-2020


APPENDIX: COMPANY LISTING

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Germany Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Patient Monitor

Germany Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Patient Monitor

  • $ 5995
  • Industry report
  • November 2016
  • by Global Data

Germany Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-El ...

Australia Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Patient Monit

Australia Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Patient Monit

  • $ 5995
  • Industry report
  • November 2016
  • by Global Data

Australia Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro- ...

India Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Patient Monitorin

India Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Patient Monitorin

  • $ 5995
  • Industry report
  • November 2016
  • by Global Data

India Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.